Vistagen Therapeutics, Inc.

VTGN

Explore Our Financial Data > Companies > Vistagen Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	VTGN
CIK	0001411685
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Website	vistagen.com
Phone	650-577-3600
CEO	Shawn K. Singh
Employees	40

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$699,000.00
Pre-Tax Income	$-47.30 million
Net Income	$-47.30 million
Net Income to Common	$-47.29 million
EPS	$-1.54

View All

Balance Sheet

Cash	$74.72 million
Assets	$92.31 million
Liabilities	$11.18 million
Common Equity	$81.12 million
Liabilities & Equity	$92.31 million

View All

Cash Flow Statement

Net Income	$-47.30 million
Cash From Operating Activities	$-39.02 million
Cash From Investing Activities	$-13.70 million
Cash From Financing Activities	$879,000.00
Change in Cash	$-51.84 million

View All

Calculations

NOPAT	$-36.99 million
EBITDA	$-52.22 million
Price to Earnings	N/A
Price to Book	$0.84
ROE	-46.28%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

SOUTH SAN FRANCISCO, Calif., June 02, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company’s PALISADE-3 P

Article Link

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

SOUTH SAN FRANCISCO, Calif., May 28, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York.

Article Link

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disorde

Article Link

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

SOUTH SAN FRANCISCO, Calif., April 17, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company’s poster presentations examined the age of onset of SAD in participants in t

Article Link

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

SOUTH SAN FRANCISCO, Calif., March 19, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disord

Article Link